These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35900152)

  • 61. IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in systemic sclerosis epidermis.
    Russo B; Borowczyk J; Cacialli P; Moguelet P; Truchetet ME; Modarressi A; Brembilla NC; Bertrand J; Boehncke WH; Chizzolini C
    Rheumatology (Oxford); 2022 Nov; 61(11):4558-4569. PubMed ID: 35171244
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
    Raschi E; Privitera D; Bodio C; Lonati PA; Borghi MO; Ingegnoli F; Meroni PL; Chighizola CB
    Arthritis Res Ther; 2020 Nov; 22(1):265. PubMed ID: 33168071
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta.
    Xu WD; Leroy EC; Smith EA
    J Rheumatol; 1991 Feb; 18(2):241-6. PubMed ID: 2023218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Insulin-like growth factor (IGF)-II- mediated fibrosis in pathogenic lung conditions.
    Garrett SM; Hsu E; Thomas JM; Pilewski JM; Feghali-Bostwick C
    PLoS One; 2019; 14(11):e0225422. PubMed ID: 31765403
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Positive Loop Formed by SOX11 and Periostin Upregulates TGF-β Signals Leading to Skin Fibrosis.
    Nanri Y; Nunomura S; Honda Y; Takedomi H; Yamaguchi Y; Izuhara K
    J Invest Dermatol; 2023 Jun; 143(6):989-998.e7. PubMed ID: 36584910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.
    Lindahl GE; Stock CJ; Shi-Wen X; Leoni P; Sestini P; Howat SL; Bou-Gharios G; Nicholson AG; Denton CP; Grutters JC; Maher TM; Wells AU; Abraham DJ; Renzoni EA
    Respir Res; 2013 Aug; 14(1):80. PubMed ID: 23915349
    [TBL] [Abstract][Full Text] [Related]  

  • 67. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.
    Dees C; Tomcik M; Palumbo-Zerr K; Distler A; Beyer C; Lang V; Horn A; Zerr P; Zwerina J; Gelse K; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2012 Sep; 64(9):3006-15. PubMed ID: 22549363
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Regulation of connective tissue synthesis in systemic sclerosis.
    Varga J; Bashey RI
    Int Rev Immunol; 1995; 12(2-4):187-99. PubMed ID: 7650421
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.
    Dooley A; Shi-Wen X; Aden N; Tranah T; Desai N; Denton CP; Abraham DJ; Bruckdorfer R
    Rheumatology (Oxford); 2010 Nov; 49(11):2024-36. PubMed ID: 20627968
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
    Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
    Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis.
    Usategui A; Criado G; Izquierdo E; Del Rey MJ; Carreira PE; Ortiz P; Leonard WJ; Pablos JL
    Ann Rheum Dis; 2013 Dec; 72(12):2018-23. PubMed ID: 23413283
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis.
    Akamata K; Wei J; Bhattacharyya M; Cheresh P; Bonner MY; Arbiser JL; Raparia K; Gupta MP; Kamp DW; Varga J
    Oncotarget; 2016 Oct; 7(43):69321-69336. PubMed ID: 27732568
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma.
    Ludwicka A; Ohba T; Trojanowska M; Yamakage A; Strange C; Smith EA; Leroy EC; Sutherland S; Silver RM
    J Rheumatol; 1995 Oct; 22(10):1876-83. PubMed ID: 8991985
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca2+ entry.
    Wu CY; Hsu WL; Tsai MH; Chai CY; Yen CJ; Chen CH; Lu JH; Yu HS; Yoshioka T
    PLoS One; 2019; 14(3):e0213400. PubMed ID: 30870448
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis.
    Trojanowska M
    Curr Opin Rheumatol; 2009 Nov; 21(6):623-9. PubMed ID: 19713852
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
    Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis.
    Ishibuchi H; Abe M; Yokoyama Y; Ishikawa O
    Exp Dermatol; 2010 Aug; 19(8):e111-6. PubMed ID: 20653770
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment.
    Higuchi T; Takagi K; Tochimoto A; Ichimura Y; Norose T; Katsumata Y; Masuda I; Yamanaka H; Morohoshi T; Kawaguchi Y
    Arthritis Res Ther; 2019 Apr; 21(1):103. PubMed ID: 30999934
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A20 suppresses canonical Smad-dependent fibroblast activation: novel function for an endogenous inflammatory modulator.
    Bhattacharyya S; Wang W; Graham LV; Varga J
    Arthritis Res Ther; 2016 Oct; 18(1):216. PubMed ID: 27716397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.